Intended Use: In-vitro cell culture studies In-vivo preclinical research in approved animal models Comparative peptide modification research Structure-activity relationship studies Academic and institutional research applications NOT Intended For: Human consumption or administration Therapeutic treatment or diagnosis Dietary supplementation or anti-aging products Veterinary therapeutic applications without oversight Any medical or clinical applications Safety Protocols: Use appropriate personal protective equipment Handle in well-ventilated areas or biosafety cabinet Follow institutional biosafety guidelines Dispose of waste per local regulations Consult MSDS for additional safety information
Sachan DS, Hongu N, Johnsen M: Decreasing oxidative stress with choline and carnitine in women
At 10% concentration, this delivers approximately 0.5%-2% active AHK-Cu peptide in the finished product, which is within the scientifically validated effective range
This guide covers everything researchers need to know about PTD-DBM: the science behind CXXC5 inhibition, how the Wnt/beta-catenin pathway governs follicle behavior, the preclinical evidence from published studies, application protocols including the three-pronged approach with valproic acid and microneedling, realistic expectations based on current evidence, safety considerations, and how PTD-DBM compares to other hair growth peptides like GHK-Cu and Thymulin zinc
